Population Pharmacokinetics of Oral Risperidone in Children, Adolescents and Adults with Psychiatric Disorders

Abstract

Population pharmacokinetics and Monte Carlo simulations demonstrated similar pharmacokinetics of risperidone in children, adolescents and adults.

Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients

“…In addition, autism patients show symptoms like irritability, aggressive attitude toward other or property, anxiety, self-injurious behavior, hyperactivity, and severe temper tantrums (Ghosh et al, 2013; Bowers et al, 2015). Risperidone, an atypical antipsychotic, is approved by the Food and Drug Administration (FDA) to treat disruptive behaviors associated with autism in children and adolescents(Cohen et al, 2013) demonstrating antagonism at dopamine D 2 , serotonin 5HT 2A , and adrenergic α 2 receptors (Thyssen et al, 2010). …”

An Open-Label Trial of Risperidone in Children and Adolescents with Severe Mood Dysregulation

“…This might explain why lithium did not show efficacy in those patients, suggesting that they do not need just a mood stabilizer. On the other hand, risperidone has a strong 5-HT2 action, which may have contributed to the improvement demonstrated in this trial (Thyssen et al 2010).…”

Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort

“…Because of the limited amount of measurements in the absorption phase, k a was fixed to 3.1 h -1 to achieve risperidone peak plasma concentration as reported in the literature [48,35,36] .…”